Similarly, we treated MEK inhibitor-sensitive, epithelial- 393P KP tumors with combinatorial therapy and observed no significant difference in primary tumor growth rate between single-agent AZD6244 and the combination group (Fig. 2d). Here, MAP2K7 is linked to neoplasm.